VRDN has 36-month beta value of 1.14. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VRDN is 55.85M, and currently, short sellers hold a 16.96% ratio of that float. The average trading volume of VRDN on April 25, 2024 was 901.14K shares.
VRDN) stock’s latest price update
Viridian Therapeutics Inc (NASDAQ: VRDN) has seen a decline in its stock price by -8.56 in relation to its previous close of 14.25. However, the company has experienced a -13.59% decline in its stock price over the last five trading sessions. InvestorPlace reported 2024-03-19 that Inflation has been the scourge of American households since the Covid-19 disruption. But investors can attempt to beat rising prices with stocks under $20.
VRDN’s Market Performance
Viridian Therapeutics Inc (VRDN) has seen a -13.59% fall in stock performance for the week, with a -25.75% decline in the past month and a -30.62% plunge in the past quarter. The volatility ratio for the week is 7.41%, and the volatility levels for the past 30 days are at 5.04% for VRDN. The simple moving average for the last 20 days is -18.90% for VRDN stock, with a simple moving average of -26.64% for the last 200 days.
Analysts’ Opinion of VRDN
Many brokerage firms have already submitted their reports for VRDN stocks, with Credit Suisse repeating the rating for VRDN by listing it as a “Outperform.” The predicted price for VRDN in the upcoming period, according to Credit Suisse is $51 based on the research report published on June 14, 2023 of the previous year 2023.
BTIG Research, on the other hand, stated in their research note that they expect to see VRDN reach a price target of $46. The rating they have provided for VRDN stocks is “Buy” according to the report published on June 14th, 2023.
RBC Capital Mkts gave a rating of “Outperform” to VRDN, setting the target price at $44 in the report published on May 30th of the previous year.
VRDN Trading at -25.77% from the 50-Day Moving Average
After a stumble in the market that brought VRDN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.00% of loss for the given period.
Volatility was left at 5.04%, however, over the last 30 days, the volatility rate increased by 7.41%, as shares sank -24.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.79% lower at present.
During the last 5 trading sessions, VRDN fell by -13.59%, which changed the moving average for the period of 200-days by -46.86% in comparison to the 20-day moving average, which settled at $15.85. In addition, Viridian Therapeutics Inc saw -40.17% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRDN starting from Fairmount Funds Management LLC, who purchase 476,190 shares at the price of $21.00 back on Jan 22 ’24. After this action, Fairmount Funds Management LLC now owns 1,839,954 shares of Viridian Therapeutics Inc, valued at $9,999,990 using the latest closing price.
Meisner Lara, the Chief Legal Officer of Viridian Therapeutics Inc, sale 27 shares at $28.35 during a trade that took place back on Jun 16 ’23, which means that Meisner Lara is holding 29,971 shares at $765 based on the most recent closing price.
Stock Fundamentals for VRDN
Current profitability levels for the company are sitting at:
- -810.35 for the present operating margin
- -3.21 for the gross margin
The net margin for Viridian Therapeutics Inc stands at -756.78. The total capital return value is set at -0.55. Equity return is now at value -56.80, with -51.37 for asset returns.
Based on Viridian Therapeutics Inc (VRDN), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -8.75. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -393.28.
Currently, EBITDA for the company is -235.37 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of 2344.21. The receivables turnover for the company is 3.08for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.26.
Conclusion
To put it simply, Viridian Therapeutics Inc (VRDN) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
